SAT-087 - A Case Series on the Compassionate Use of Ersodetug, an Insulin Receptor Modulating Antibody, in Patients with Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors

Abstract Poster Presenter(s)

• MP

  Mary Elizabeth Patti, MD

  Joslin Diabetes Center, United States

Senior Author/Primary Investigator(s)

• MP

  Mary Elizabeth Patti, MD

  Joslin Diabetes Center, United States

Co-Author(s)

• SB

  Sean Brown, MD

  Harvard University
  Boston, Massachusetts, United States
• JD

  Jonathan Dreyfuss, PhD

  Joslin Diabetes Research Center
  Boston, Massachusetts, United States

Senior Author/Primary Investigator(s)

• SS

  Shagufta Shaheen, MD

  Stanford University
  Palo Alto, California, United States
• 

  Marilyn Tan, MD

  Clinical Professor
  STANFORD UNIVERSITY MEDICAL CENTER
  Los Altos, CA, United States
• AY

  Armen Yerevanian, MD

  Massachusetts General Hospital
  Boston, Massachusetts, United States
• LL

  Linda Lester, MD

  OHSU
  Portland, Oregon, United States
• LW

  Leah Wilson, MD

  OHSU
  Portland, Oregon, United States
• OH

  Ole-Petter Hamnvik, MBBChBAO,MMSc,MRCPI

  Associate Professor of Medicine
  Brigham and Women's Hospital
  Winchester, MA, United States
• JH

  Johannes Hofland, MD

  Erasmus MC
  Rotterdam, Netherlands

Co-Author(s)

• CJ

  Christina Jobson, n/a

  Rezolute, Inc.
  Redwood City, California, United States
• GS

  Gopal Saha, MBBS

  Rezolute Inc.
  Redwood City, California, United States
• BR

  Brian Roberts, MD

  Rezolute, Inc
  Redwood City, California, United States

Senior Author/Primary Investigator(s)

• JS

  Jonathan Strosberg, MD

  Moffitt Cancer Center
  Tampa, Florida, United States